Skip to main content
Clinical Trials/NCT06337708
NCT06337708
Recruiting
Phase 2

Smart Walk: An Efficacy Trial of a Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women

Arizona State University1 site in 1 country240 target enrollmentApril 8, 2024

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Physical Activity
Sponsor
Arizona State University
Enrollment
240
Locations
1
Primary Endpoint
Change in accelerometer-measured moderate-to-vigorous intensity physical activity from baseline to 4- and 12-months
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

The purpose of this study is to test a culturally tailored, smartphone-delivered intervention designed to increase physical activity and reduce risk for heart disease and type 2 diabetes among African American women.

Detailed Description

This study addresses major public health concerns among African American women: physical inactivity and cardiometabolic disease risk. African American women experience a high burden of cardiometabolic diseases, including heart disease, obesity, and type 2 diabetes. Regular aerobic physical activity is an established behavior to prevent and treat these conditions. Yet, the many African American women are insufficiently active, with only 27-40% meeting national aerobic physical activity guidelines. This study will test the efficacy of Smart Walk, a culturally tailored, theory-based smartphone-delivered intervention designed to increase physical activity and improve cardiometabolic disease risk factors among African American women. In a 12-month trial, participants will be randomly assigned to either the Smart Walk intervention or a Fitbit-only comparison arm for an active 4-month intervention period, followed by an 8-month minimal contact follow-up period. Specific Aims: 1. Test the effects of Smart Walk to increase physical activity and promote adherence to national aerobic physical activity guidelines; compared to Fitbit-only comparison group. 2. Test the effects of Smart Walk to improve cardiometabolic risk factors; compared to Fitbit-only comparison group. 3. Compare cost and cost effectiveness of the two intervention groups from a societal perspective. 4. Examine if protocol adherence predicts outcomes and potential mediation and moderation of intervention effects on physical activity and cardiometabolic outcomes.

Registry
clinicaltrials.gov
Start Date
April 8, 2024
End Date
March 31, 2028
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Self-reported African American/Black female
  • Aged of 24-65 years
  • Insufficiently Active (\< 60 minutes of moderate-to-vigorous physical activity per week as measured by Exercise Vital Sign Questionnaire)
  • BMI \> 30 kg/m2
  • English speaking and reading
  • Ownership of a smartphone with the ability to download applications (i.e., apps)
  • Ownership of a smartphone with the ability to receive text messages
  • Willingness to receive a physical activity intervention delivered through their smartphone
  • Willingness to include their first name or create an alias to be used on their profile page on the Smart Walk app

Exclusion Criteria

  • Plans to relocate out of Phoenix area in next 12 months
  • Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a doctor's note for study participation in provided
  • Resting systolic blood pressure greater than 180 mmHG and/or a diastolic blood pressure greater than 120 mmHG , as assessed at baseline or at any other study assessment
  • Self-reported participation in another diet or weight loss study at screening
  • Pregnant or planning to become pregnant in the next 12 months

Outcomes

Primary Outcomes

Change in accelerometer-measured moderate-to-vigorous intensity physical activity from baseline to 4- and 12-months

Time Frame: Assessed at baseline, 4-months, 12-months

Participants will wear wrist-worn ActiGraph GT9X Link Activity monitors the activity monitor on their non-dominant wrist during all waking hours for 7 consecutive days to provide an assessment of usual activity

Change in self-reported moderate-to-vigorous intensity physical activity from baseline to 4- and 12-months

Time Frame: Assessed at baseline, 4-months, 12-months

Assessed by the 7-Day Physical Activity Recall

Secondary Outcomes

  • Change in cardiorespiratory fitness from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in waste circumference from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in tumor necrosis factor-alpha (TNF-α) from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in interleukin 6 (IL-6) from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in interleukin 10 (IL-10) from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in serum insulin from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in blood pressure (mmHG) from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in self-regulation for physical activity from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in aortic pulse wave velocity from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in body weight from baseline to 4- and 12-months.(Assessed at baseline, 4-months, 12-months)
  • Change in behavioral capability for physical activity from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in body mass index from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in serum lipids (mg/DL) from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in exercise self-efficacy from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in interleukin 15 (IL-15) from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in fasting blood glucose glucose from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in insulin sensitivity (µIU/mL) from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in social support for physical activity from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)
  • Change in outcome expectations for physical activity from baseline to 4- and 12-months(Assessed at baseline, 4-months, 12-months)

Study Sites (1)

Loading locations...

Similar Trials